БЕРРИ Линн (US),ФИЛЛИПС Гейл Льюис (US),СЛИВКОВСКИ Марк Кс. (US)
申请号：
RU2013147514/15
公开号：
RU2013147514A
申请日:
2013.10.24
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating a hyperproliferative disorder, comprising administering a therapeutic combination in the form of a combination composition, or alternately to a mammal, wherein the therapeutic combination comprises a therapeutically effective amount of trastuzumab-MCC-DM1 and a therapeutically effective amount of pertuzumab. The method of claim 1, wherein a therapeutically effective amount of trastuzumab-MCC-DM1 and a therapeutically effective amount of pertuzumab are administered as a combined composition. The method of claim 1, wherein the therapeutically effective amount of trastuzumab-MCC-DM1 and the therapeutically effective amount of pertuzumab are administered alternately. The method of claim 1, wherein the mammal is administered pertuzumab and then trastuzumab-MCC-DM1.5 is subsequently administered. The method according to any one of paragraphs. 1-4, where the therapeutic combination is administered to a person with hyperproliferative disorder at intervals of approximately three weeks. The method according to any one of paragraphs. 1-4, where trastuzumab-MCC-DM1 is administered to a person with hyperproliferative disorder at intervals of about one week to three weeks. The method according to any one of paragraphs. 1-4, where trastuzumab-MCC-DM1 is administered no more often than every 3 weeks at a dosage of 2.4, 3.0, or 3.6 mg / kg intravenously. 8. The method according to any one of paragraphs. 1-4, where the amount of trastuzumab-MCC-DM1 and the amount of pertuzumab for each is from about 1 mg to about 1000 mg, and the amounts of trastuzumab-MCC-DM1 and the amount of pertuzumab are in a ratio of from about 1:10 to about 10: 1 by weight .9. The method according to any one of paragraphs. 1-4, where the hyperproliferative disorder is a malignant tumor expressing ErbB2.10. The method according to any one of paragraphs. 1-4, where the mammal is a patient with1. Способ лечения гиперпролиферативного нарушения, включающий введение терапевтической комбинации
